Pharmaceutics The science of dosage form design

Edited by M E Aulton

Churchill Livingstone 🏥



CHURCHILL LIVINGSTONE

Medical Division of Longman Group UK Limited Distributed in the United States of America by Churchill Livingstone Inc., 650 Avenue of the Americas, New York, 10011, and associated companies, branches and representatives throughout the world.

© Michael Aulton 1988

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publishers (Churchill Livingstone, Robert Stevenson House, 1-3 Baxter's Place, Leith Walk, Edinburgh EH1 3AF), or a Licence permitting restricted copying in the United Kingdom issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London, W1P 9HE.

First published 1988

Reprinted 1989

Reprinted 1990

Reprinted 1991

Reprinted 1992

8-E44E0-E44-0 NBZI

British Library Cataloguing in Publication Data Pharmaceutics: the science of dosage form design.

1. Pharmaceutics

I. Aulton, Michael E.

615'.19 RS403

Library of Congress Cataloging in Publication Data Pharmaceutics: the science of dosage form design. Replaces: Cooper and Gunn's tutorial pharmacy. 6th ed. 1972.

Includes bibliographies and index.

1. Drugs — Design of delivery systems. 2. Drugs

- Dosage forms. 3. Biopharmaceutics.

4. Pharmaceutical technology. 5. Chemistry, Pharmaceutical. 6. Microbiology, Pharmaceutical. I. Aulton, Michael E.

[DNLM: 1. Biopharmaceutics. 2. Chemistry,

Pharmaceutical. 3. Dosage Forms. 4. Technology,

Pharmaceutical. 5. Microbiology, Pharmaceutical.

QV 785 P5366]

RS420.P48 1987 615.5'8 86-2588

Printed in Hong Kong CPP/05 The publisher's policy is to use paper manufactured from sustainable forests



Contents

		•	
Preface	vii	PART FOUR Pharmaceutical	
Contributors	ix	microbiology	423
Acknowledgements	xi	24 Fundamentals of microbiology	425
About this book	xiii	25 The action of physical and chemical	
1. The design of desage forms	1	agents on micro-organisms	452
1 The design of dosage forms	1	26 Principles of sterilization	472
PART ONE Physicochemical		27 Microbiological contamination and	
principles of pharmaceutics	15	preservation of pharmaceutical	
2 Rheology and the flow of fluids	17	preparations	479
3 Solutions and their properties	38	28 Pharmaceutical applications of	
4 Surface and interfacial phenomena	50	microbiological techniques	491
5 Solubility and dissolution rate	62	DADTE EINE DI	
6 Disperse systems	81	PART FIVE Pharmaceutical	500
7 Kinetics and stability testing	119	technology	509
PART TWO Biopharmaceutics	120	29 Materials of fabrication and corrosion	511
8 Introduction to biopharmaceutics	129 131	30 Heat transfer and the properties of	
9 Factors influencing bioavailability	131	steam	525
10 Assessment of bioavailability	174	31 Filtration	538
11 Dosage regimens	191	32 Mixing	550
11 Dosage regimens	191	33 Particle size analysis	564
PART THREE Drug delivery systems	213	34 Particle size reduction	581
12 Packs for pharmaceutical products	215	35 Particle size separation	591
13 Preformulation	223	36 Powder flow	600
14 Solutions	254	37 Granulation	616
15 Suspensions	269	38 Drying	629
16 Emulsions	282	39 Tableting	647
17 Powders and granules	300	40 Tablet coating	669
18 Tablets	304	41 Encapsulation	678
19 Capsules	322	42 Design and operation of clean rooms	686
20 Therapeutic aerosols	341	43 Sterilization practice	700
21 Parenteral products	359	. 44 Packaging technology	712
22 Topical preparations	381	Index	725
23 Suppositories and pessaries	412		, 2 5



The design of dosage forms

PRINCIPLES OF DOSAGE FORM DESIGN

BIOPHARMACEUTICAL CONSIDERATIONS IN DOSAGE FORM DESIGN

Routes of drug administration

Oral route Rectal route

Parenteral route
Topical route

Respiratory route

DRUG FACTORS IN DOSAGE FORM DESIGN

Organoleptic properties
Particle size and surface area
Solubility
Dissolution
Partition coefficient and pK_a Crystal properties; polymorphism

Stability
Other drug properties

THERAPEUTIC CONSIDERATIONS IN DOSAGE FORM DESIGN

SUMMARY

PRINCIPLES OF DOSAGE FORM DESIGN

Drugs are rarely administered solely as pure chemical substances but are almost always given in formulated preparations. These can vary from relatively simple solutions to complex drug delivery systems, through the use of appropriate additives or excipients in the formulations to provide varied and specialized pharmaceutical functions. It is the formulation additives that, amongst other things, solubilize, suspend, thicken, preserve, emulsify, improve the compressibility and flavour drug substances to form various preparations or dosage forms.

The principal objective of dosage form design is to achieve a predictable therapeutic response to a drug included in a formulation which is capable of large scale manufacture with reproducible product quality. To ensure product quality, numerous features are required - chemical and physical stability, with suitable preservation against microbial contamination if appropriate, uniformity of dose of drug, acceptability to users including both prescriber and patient, as well as suitable packaging and labelling. Ideally, dosage forms should also be independent of patient to patient variation although in practice this feature remains difficult to achieve. Future developments in dosage form design may well attempt to accommodate to some extent this requirement.

Reference is made in Part 2 of this book to differences in bioavailability between apparently similar formulations and possible causative reasons. In recent years increasing attention has therefore been directed towards eliminating variation in bioavailability characteristics, particularly for chemically equivalent products since it is



recognized that formulation factors can influence their therapeutic performance. To optimize the bioavailability of drug substances it is often necessary to carefully select the most appropriate chemical derivative of the drug, for example to obtain a specific solubility requirement, as well as its particle size and physical form, to combine it with appropriate additives and manufacturing aids that will not significantly alter the properties of the drug, to select the most appropriate administration route(s) and dosage form(s) and to consider aspects of manufacturing processes and suitable packaging.

There are numerous dosage forms into which a drug substance can be incorporated for the convenient and efficacious treatment of a disease. Dosage forms can be designed for administration by all possible delivery routes to maximize therapeutic response. Preparations can be taken orally or injected, as well as being applied to the skin or inhaled, and Table 1.1 lists the range of dosage forms which can be used to deliver drugs by the various administration routes. However, it is necessary to relate the drug substance and the disease state before the correct combination of drug and dosage form can be made since each disease or illness will require a specific type of drug therapy. In addition factors governing choice of administration route and the specific require-

Table 1.1 Range of dosage forms available for different administration routes

Administration route	Dosage forms
Oral	Solutions, syrups, elixirs, suspensions, emulsions, gels, powders, granules, capsules, tablets
Rectal	Suppositories, ointments, creams, powders, solutions
Topical	Ointments, creams, pastes, lotions, gels, solutions, topical aerosols
Parenteral	Injections (solution, suspension, emulsion forms), implants, irrigation and dialysis solutions
Lungs	Aerosols (solution, suspension, emulsion, powder forms), inhalations, sprays, gases
Nasal	Solutions, inhalations
Eye	Solutions, ointments
Ear	Solutions, suspensions, ointments

ments of that route which affect drug absorption need to be taken into account when designing dosage forms.

Versatile drugs are often formulated into several dosage forms of varying strengths, each having particular pharmaceutical characteristics which are suitable for a specific application. One such drug is the glucocorticoid prednisolone. Through the use of different chemical forms and formulation additives a range of effective anti-inflammatory preparations are available including tablet, enteric coated tablet, injections, eye drops and enema. The extremely low aqueous solubility of the base prednisolone and acetate salt makes these forms useful in tablet and slowly absorbed intramuscular suspension injection forms, whilst the soluble sodium phosphate salt enables a soluble tablet form, and solutions for eye drops, enema and intravenous injection to be prepared. The antibacterial drug combination co-trimoxazole, consisting of a mixture of five parts of sulphamethoxazole and one part trimethoprim, is also available in a range of dosage forms and strengths to meet specific needs of the user, including tablets, dispersible tablets, double strength tablets, double strength dispersible tablets, paediatric mixture, intramuscular injection, and a strong sterile solution for the preparation of an intravenous infusion. Because of the low aqueous solubility of both drug substances, specialized solvents are used for the intramuscular injection: 52% glycofurol, and strong sterile solution, 40% propylene glycol.

It is therefore apparent that before a drug substance can be successfully formulated into a dosage form many factors must be considered. These can be broadly grouped into three categories:

- 1 biopharmaceutical considerations, including factors affecting the absorption of the drug substance from different administration routes,
- 2 drug factors, such as the physical and chemical properties of the drug substance, and
- 3 therapeutic considerations including consideration of the disease to be treated and patient factors.

Appropriate and efficacious dosage forms will be prepared only when all these factors are



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

